ClearRead CT

by RIVERAIN TECHNOLOGIES  · Based in United States →AI-Driven Clarity for Faster & More Confident Nodule Detection
Cardiology Pulmonology Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

ClearRead™ CT by Riverain Technologies is a cardiothoracic AI suite designed to enhance the accuracy and efficiency of disease detection in chest CT scans. It leverages advanced AI algorithms and patented vessel suppression technology to provide an unimpaired view of the lung, aiding radiologists in identifying and characterizing pulmonary nodules and assessing coronary artery calcification (CAC).

The suite comprises several powerful tools: ClearRead CT Vessel Suppress, which removes vessels and other normal structures to improve nodule conspicuity; ClearRead CT Detect, which automatically detects, segments, and measures critical properties of solid, sub-solid, and ground glass nodules; and ClearRead CT Compare, which tracks nodules over time and provides precise volumetric change measurements for comparative analysis.

ClearRead CT is proven to reduce total reading time by up to 36% and decrease missed actionable nodules by 29%, easing cognitive burden and improving diagnostic confidence. It seamlessly integrates into existing PACS workflows, supporting concurrent reading without the need for additional hardware or separate viewers. The solution is enterprise-ready, processing scans from all CT manufacturers and acquisition protocols.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Pulmonary Nodule Detection (solid, part-solid, ground glass)
  • Patented Vessel Suppression (Clear Visual Intelligence)
  • Nodule Characterization and Measurement (volume, diameter, location, type, depth)
  • Automated Nodule Tracking and Comparison to Prior Exams
  • Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs)
  • Reduced Reading Time (up to 36%)
  • Improved Detection Accuracy (29% reduction in missed actionable nodules)
  • Seamless PACS Integration / Vendor-neutral processing
  • Enterprise-wide capability across CT manufacturers and protocols
  • Automated Report Generation

Use Cases

  • Lung Cancer Screening Programs
  • Early Detection and Characterization of Lung Disease
  • Cardiothoracic Disease Detection and Analysis
  • Pulmonary Nodule Management and Surveillance
  • Enhancing Radiology Workflow Efficiency
  • Opportunistic Screening for Coronary Heart Disease

What Physicians Need to Know

Cardiac CT/MRI Analysis
ClearRead CT, as a cardiothoracic AI suite, includes analysis of Coronary Artery Calcification (CAC) on ungated, non-contrast CT exams. It accurately detects, quantifies, and reports Agatston scores.
Heart Failure Risk Prediction
By accurately scoring Coronary Artery Calcification (CAC) on routine CTs, ClearRead CT aids in identifying patients at risk for atherosclerotic cardiovascular disease, which is a proven predictor of future cardiac events and a leading cause of heart failure.
Coronary Artery Assessment
ClearRead CT CAC provides AI-powered precision for opportunistic detection, quantification, and Agatston scoring of coronary artery calcification on ungated, non-contrast chest CT scans. It also calculates 'arterial age'.
Cardiac Monitoring Integration
ClearRead CT is an imaging analysis tool and does not integrate with cardiac monitoring systems.
AHA/ACC Guideline Alignment
While not explicitly stating direct AHA/ACC guideline alignment, the tool's focus on Agatston scoring for CAC aligns with established cardiovascular risk assessment practices, enabling opportunistic screening for atherosclerotic cardiovascular disease.
Real-Time Alert Capability
ClearRead CT integrates findings into the radiology report, providing timely insights for earlier intervention and assessment of cardiac risk from routine CTs.
Physician Tip

Leverage ClearRead CT's Coronary Artery Calcification (CAC) scoring on routine, ungated chest CTs to opportunistically identify patients at risk for cardiovascular disease who might otherwise go undetected. This can facilitate earlier intervention and improve patient outcomes by integrating cardiac risk assessment into existing lung cancer screening or other chest CT workflows. The Agatston score and 'arterial age' provide valuable quantitative data for risk stratification.

ClearRead CT outputs findings in DICOM format, making it readable in Picture Archiving and Communication Systems (PACS). It supports seamless workflow with concurrent reading, often integrating as an additional series in the patient study without requiring a separate viewer or logins. ROI contours and measurements can be exported as overlay objects or DICOM SC objects, and pre-populated reports are available.

Details

Category Cardiology AI, Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing Contact vendor for details
DeploymentOn-premise (stand-alone server, virtual machine) and Cloud
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

ClearRead CT received FDA 510(k) clearance (K161201) on September 9, 2016, as a computer-aided detection (CAD) system intended to aid radiologists in the detection of pulmonary nodules during review of CT examinations of the chest on an asymptomatic population. It was the first FDA-cleared device to support concurrent reading. More recent clearances (as of February 2025) extend its functionality to include coronary artery calcium (CAC) scoring for ungated, non-contrast CTs.

Integrations
EHR Not specified
Specialties Cardiology, Pulmonology, Radiology

What the Web Says

ClearRead CT by Riverain Technologies is an AI-powered software designed to assist radiologists in detecting and characterizing pulmonary nodules in chest CT scans, particularly for lung cancer screening and surveillance. It aims to improve reading efficiency and accuracy by providing an unimpaired view of the lungs through vessel suppression and acquisition normalization technologies. The software integrates with existing PACS systems, allowing radiologists to view processed images alongside original CT series without needing a separate application.

Overall: Positive

Strengths

  • Increased nodule detection rates, especially for small nodules (u22642 mm).
  • Reduced reading times for radiologists.
  • Improved interreader agreement.
  • Seamless integration with existing PACS and workflow.
  • Easy installation and adaptability to changing CT protocols.
  • Ability to quantify incidental coronary artery calcification (CAC) on ungated CT exams.

Limitations

  • Limited scientific data on the use of the software at one point, prompting a study to confirm accuracy and efficiency.
  • Not intended for monitoring patients undergoing therapy for lung cancer or limited field of view CT scans.
  • Provides adjunctive information and is not intended to be used without the original CT series.
  • Some general AI services for CT reads have been noted to frequently miss clinically relevant findings outside of specific diagnoses.
  • No specific negative reviews found on G2 or Capterra for ClearRead CT, but general concerns about AI in radiology include potential for missed findings and the need for radiologist oversight.

Based on reviews from: accessdata.fda.gov, Imaging Wire, Riverain Technologies, 3DR Labs, AuntMinnie, Reddit, G2, Capterra

Last updated: 2026-07-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ClearRead CT

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Riverain Technologies
Study Shows ClearReadu2122 CT CAC for Incidental Coronary Artery Calcification Highly Effective on Ungated CT Exams
A new study published in Scientific Reports demonstrates that Riverain Technologies' ClearReadu2122 CT CAC technology shows high agreement with radiologists and gated cardiac exams for scoring incidental coronary artery calcification on ungated CT exams. This technology aims to improve the incidental detection of CAC and identify patients at risk for cardiovascular disease.
2025-11
Riverain Technologies
Riverain Technologies Expands Globally in 2024, Launches New FDA-Cleared Technology
Riverain Technologies expanded into eight countries and gained nearly 50 new customers in 2024, achieving 147% year-over-year growth. The company is entering 2025 with new FDA-cleared technology that extends ClearRead CT functionality to include coronary artery calcium (CAC) scores for ungated scans.
2025-02
Riverain Technologies
Riverain Technologies Announces Health Canada Approval of ClearRead CT CAC for Opportunistic Coronary Artery Calcification Quantification
Riverain Technologies received Health Canada approval for ClearRead CT CAC, an AI solution for opportunistic coronary artery calcification quantification on ungated, non-contrast chest CT exams. This approval allows Canadian radiologists to use the technology for early detection and risk stratification of cardiovascular disease.
2025-03
Riverain Technologies
deepc Enriches Enterprise Health AI Portfolio with Riverain Technologies' ClearReadu2122 solutions on deepcOS
deepc has integrated Riverain Technologies' FDA-cleared and CE-marked ClearReadu2122 CT and ClearReadu2122 XR into its deepcOSu00ae Enterprise AI Infrastructure. This integration aims to enhance chest imaging interpretation through vessel suppression, nodule detection, and incidental coronary artery calcium scoring.
2025-11
Aidoc Blog
Riverain Technologies and Aidoc: Faster Reads and Improved Nodule Detection
A University of Washington School of Medicine study, presented at RSNA 2024, demonstrated that integrating Riverain Technologies' ClearReadu2122 CT through Aidoc's aiOSu2122 platform reduced radiology residents' reading times by 36% and improved detection rates for small pulmonary nodules.
2025-02
Signal Akron
How Northeast Ohio hospitals are using AI to improve medical care
Northeast Ohio hospitals, including University Hospitals and Cleveland Clinic, are utilizing AI in radiology. Riverain Technologies' ClearRead CT is used for automated detection and characterization of lung nodules on CT scans, with studies showing it can read a patient scan in about 4 minutes.
2026-02
Riverain Technologies (citing Scientific Reports)
Evaluation of an artificial intelligence model for opportunistic Agatston scoring on non-gated chest computed tomography
This study, published in Scientific Reports, assessed the performance of Riverain Technologies' ClearRead CT CAC in estimating Agatston scores from non-contrast, non-gated chest CTs. The AI model showed high agreement with ground truth radiologists and paired gated CTs, suggesting its potential for opportunistic screening of atherosclerotic cardiovascular disease.
2025-11
FDA
K242188 - 510(k) Premarket Notification - ClearRead CT CAC
This FDA 510(k) Premarket Notification details the clearance for Riverain Technologies, Inc.'s ClearRead CT CAC, classified under product code JAK.
2026-03

Videos

Product demos, reviews, and walkthroughs for ClearRead CT.

View all on YouTube

Frequently Asked Questions

ClearRead CT seamlessly integrates into existing Picture Archiving and Communication Systems (PACS) workflows, appearing as an additional series in the patient study without requiring separate viewers or hardware. It leverages AI for vessel suppression (ClearRead CT Vessel Suppress) to improve nodule conspicuity and provides automatic nodule detection, segmentation, and characterization (ClearRead CT Detect), including volumetric measurements.
ClearRead CT has received U.S. FDA 510(k) clearance as a Class II device and holds the CE Mark (Class IIa under MDR), being the first FDA-cleared device for concurrent reading and all nodule types. Regarding data privacy, ClearRead CT does not store patient data in a database; scans are processed and sent to PACS via DICOM, supporting role-based authentication and authorization in compliance with relevant security standards.
ClearRead CT is intended as an aid to interpretation, and physicians must use the original chest CT series for diagnostic interpretation, remaining responsible for confirming all results. It is designed for asymptomatic and non-oncological patient populations, requiring both lungs in the field of view, and is not cleared for pediatric use or for monitoring patients undergoing lung cancer therapy.
The exact pricing for ClearRead CT is not publicly disclosed and varies based on the country, specific pricing model, and local negotiations. Common pricing models include one-time license fees or subscriptions, which are often determined by factors such as the number of analyses performed.
Several AI-powered solutions exist for chest CT analysis, including Infervision's InferRead CT Lung and Qure.ai's qLC-Suite. ClearRead CT differentiates itself through its patented vessel suppression technology, which provides an unimpaired view of the chest, and its FDA clearance for concurrent reading and detection of all nodule types (solid, sub-solid, ground-glass).
Clinical trials and studies have demonstrated that ClearRead CT can lead to a 29% reduction in missed actionable nodules and a 26-36% reduction in reading time for radiologists. This improvement in efficiency and accuracy is attributed to its AI-powered vessel suppression and automatic nodule detection capabilities.
ClearRead CT is intended for the detection and characterization of pulmonary nodules during the review of screening and surveillance (low-dose) CT examinations of the chest on an asymptomatic, non-oncological patient population. It is not intended for monitoring patients undergoing therapy for lung cancer, limited field of view CT scans, or for pediatric use.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

More from Riverain Technologies

CLEARREAD +CONFIRM
RIVERAIN TECHNOLOGIES
Radiology & Imaging AI
CLEARREAD +CONFIRM is an AI tool by Riverain Technologies that enhances chest X-ray images to improve the visibility and confirmation of lines and tubes, reducing reading time by approximately 19% for radiologists.
ClearRead CT CAC
Riverain Technologies
Cardiology AI
ClearRead CT CAC by Riverain Technologies is an AI-powered software that enables opportunistic screening for coronary artery calcification (CAC) by accurately detecting, quantifying, and reporting Agatston scores from routine, ungated, non-contrast chest CT scans.
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.
DELTAVIEW MODEL
Riverain Technologies
Oncology AI
DELTAVIEW MODEL, by Riverain Technologies (formerly Riverain Medical Group), is an AI-driven medical imaging software for temporal comparison of chest X-rays, designed to detect subtle changes like early-stage lung cancer nodules through bone suppression and image subtraction technology.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-22 | First Added: 2026-04-22
AI Tool Finder
AI-powered search. Results may not be comprehensive.